Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GABAA agonists as targets for drug development.

G A Johnston1

  • 1Adrien Albert Laboratory of Medicinal Chemistry, Department of Pharmacology, University of Sydney, New South Wales, Australia.

Clinical and Experimental Pharmacology & Physiology
|January 1, 1992
PubMed
Summary

Researchers developed novel drugs by restricting the conformation of GABA molecules, leading to potential new analgesics and anthelmintics. These findings suggest diverse GABAA receptor subtypes that can be targeted for drug development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current prevalence and relevance of positive patch test reactions to cosmetic and noncosmetic isothiazolinones in the UK.

The British journal of dermatology·2021
Same author

Occupational dermatoses during the COVID-19 pandemic: a multicentre audit in the UK and Ireland.

The British journal of dermatology·2020
Same author

Prevalence of allergic contact dermatitis to decyl and lauryl glucoside in the UK and Ireland.

The British journal of dermatology·2020
Same author

What is in? What is out? Updating the British Society for Cutaneous Allergy facial series.

The British journal of dermatology·2020
Same author

Allergic contact dermatitis to nonmethacrylate nail allergens in the UK.

The British journal of dermatology·2020
Same author

Recommendation to include hydroxyethyl (meth)acrylate in the British baseline patch test series.

The British journal of dermatology·2019

Area of Science:

  • Neuroscience
  • Pharmacology
  • Medicinal Chemistry

Background:

  • GABAA receptors are crucial in the central nervous system.
  • Developing selective modulators for GABAA receptors is a key therapeutic goal.
  • Existing drugs targeting GABAA receptors lack specificity.

Purpose of the Study:

  • To develop novel GABAA receptor modulators by restricting GABA's conformational mobility.
  • To explore the therapeutic potential of these conformationally restricted analogues.
  • To investigate the heterogeneity of GABAA receptors.

Main Methods:

  • Systematic conformational restriction of the GABA molecule.
  • Synthesis and pharmacological evaluation of novel GABA analogues (THIP, ZAPA, (+)-TACP).

Related Experiment Videos

  • Utilizing pharmacological, molecular modeling, and molecular biology techniques.

    • Main Results:

    • THIP, a conformationally restricted GABA analogue, demonstrated potent analgesic properties comparable to morphine and acts independently of opiate systems.
    • ZAPA, another analogue, selectively activates low-affinity GABAA receptors and shows potential as an anthelmintic.
    • (+)-TACP may target a distinct GABAA receptor subclass.
    • Evidence for GABAA receptor heterogeneity was established.

    Conclusions:

    • Conformationally restricted GABA analogues represent a promising strategy for developing novel therapeutics.
    • THIP and ZAPA are lead compounds for new analgesics and anthelmintics, respectively.
    • The identified GABAA receptor heterogeneity offers opportunities for targeted drug discovery.